Valion Bio (VBIO) Profit After Tax Growth (1y) (2022 - 2026)
Valion Bio (VBIO) Profit After Tax Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -8.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.21% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 151.28% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 327.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -228.03% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 94.83% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -12.04% |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | 97.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -708.65% |
| Dec 31, 2025 | 105.02% |
| Sep 30, 2025 | -81.41% |
| Jun 30, 2025 | -52.53% |
| Mar 31, 2025 | -1.42% |
| Dec 31, 2024 | 35.13% |
| Sep 30, 2024 | 18.69% |
| Jun 30, 2024 | 40.42% |
| Mar 31, 2024 | 30.01% |
| Dec 31, 2023 | 0.49% |
| Sep 30, 2023 | 31.89% |
| Jun 30, 2023 | 29.59% |
| Mar 31, 2023 | 5.54% |
| Dec 31, 2022 | 39.47% |
| Sep 30, 2022 | -11.38% |
| Jun 30, 2022 | -175.87% |
| Mar 31, 2022 | -65.19% |